MedTrace Logo

CGM Use in Islet Transplant Recipients

NCT03427931 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-08-07

Study results available
· View outcomes & findings →

Summary

A study assessing glucose variability in subjects with Type 1 Diabetes who have had islet transplant.

Conditions

  • Islet Transplantation
  • Type1 Diabetes Mellitus

Interventions

OTHER

Continuous Glucose Monitor (CGM)

Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of Virginia

    lead OTHER

Principal Investigators

  • Sue A Brown, MD · University of Virginia

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-07-11
Completion
2019-07-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03427931 on ClinicalTrials.gov